Average Co-Inventor Count = 2.81
ph-index = 30
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Amylin Pharmaceuticals, Inc. (53 from 164 patents)
2. Satiogen Pharmaceuticals, Inc. (9 from 9 patents)
3. Astrazeneca Pharmaceuticals LP (7 from 38 patents)
4. Intarcia Therapeutics, Inc. (4 from 67 patents)
5. Other (1 from 832,887 patents)
6. I2o Therapeutics, Inc. (1 from 8 patents)
68 patents:
1. 11840559 - Glucagon-receptor selective polypeptides and methods of use thereof
2. 11654183 - Methods comprising continuous administration of exenatide and co-administration of a drug
3. 11260053 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
4. 11214607 - Glucagon-receptor selective polypeptides and methods of use thereof
5. 10835580 - Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
6. 10555950 - Bile acid recycling inhibitors for treatment of obesity and diabetes
7. 10501517 - Glucagon-receptor selective polypeptides and methods of use thereof
8. 10251880 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
9. 10188646 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
10. 10028952 - Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof
11. 9345715 - Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof
12. 9339480 - Bile acid recycling inhibitors for treatment of obesity and diabetes
13. 9133260 - GIP analog and hybrid polypeptides with selectable properties
14. 8951962 - Modified exendins and exendin agonists
15. 8895498 - GIP and exendin hybrid polypeptides